![](https://investorshub.advfn.com/uicon/430424.png?cb=1554906782)
Saturday, April 06, 2019 9:23:14 AM
With CIs (and Car-Ts for that matter), researches are asking the antibodies (or t-cells) to do something the human evolutionary system did not design them to do. With CIs, they are taking away the ability of the body to intermittently turn off its own t-cell response, with Car-ts, they are asking the immune cells to specifically target B-cell cancer as well as healthy B-cells. Nature doesn't destroy all its healthy B cells to fight cancer.
DCVax-L instead reminds the immune system not to be put to sleep by cancer's signaling, and develops the best and the brightest DCs to instruct the t-cells to go after the tumor targets. Nature developed a lock and key selection system, and DCVax-l leverages that system by getting the tumor and non-suppressed DCs together outside the body. After vaccine, the patient response, when it occurs, is typically a reawakened (aka: not suppressed) immune system that stops/stabalizes cancer.
CIs are essentially akin to putting soldiers on duty 24/7 with no rest to attack first and ask questions later...."oops, sorry about your kidneys, arthritis, etc....my bad....yawn... got any coffee?"
DCVax-L is essentially akin to generals and soldiers doing their job through thoughtful coordination/communication without being tricked into ignoring danger. Your body is fighting potential cancer every day. No big deal. Typically it will isolate and slowly rid the body of precancerous foes. DCVax-L, when it works, takes care of cancer within the bounds of your immune system's evolutionary playbook.
Respect Risk. Conduct Your Own Due Diligence. Manage your assets wisely. Diversify.
Recent NWBO News
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/30/2024 11:49:38 PM
- Biophma Announces Exclusive In License for Dendritic Cell Technology, Sending Shares Higher • AllPennyStocks.com • 06/17/2024 04:40:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/04/2024 09:11:16 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 06/03/2024 09:22:55 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 05/22/2024 08:13:36 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/10/2024 09:04:57 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/01/2024 10:04:38 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/02/2023 01:31:35 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/16/2023 10:11:54 PM
- Epazz, Inc. (OTC Pink: EPAZ) ZenaDrone Demonstration to Defense Departments of UAE and Saudi Arabia • InvestorsHub NewsWire • 11/15/2023 12:19:31 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/09/2023 09:30:39 PM
- Epazz, Inc. (OTC Pink: EPAZ) US Navy Collaboration ZenaDrone 1000 • InvestorsHub NewsWire • 11/09/2023 01:00:34 PM
- Epazz, Inc. (OTC Pink: EPAZ) US Navy Collaboration ZenaDrone 1000 Extreme Weather Demo • InvestorsHub NewsWire • 11/07/2023 12:29:43 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/09/2023 08:36:14 PM
FEATURED ELEMENT79 GOLD CORP PROVIDES UPDATE ON CHACHAS COMMUNITY CHARTER AND REVENUE GENERATION, M&A ACTIVITIES • Jul 30, 2024 8:00 AM
Avant Technologies Opens Equity Line with GHS Investments as Company Explores Expansion into Additional Technologies • AVAI • Jul 30, 2024 8:00 AM
INDEXR AI Merges With Moon Equity Holdings Corp. (MONI), Creating a Leading-edge Technology Company • MONI • Jul 29, 2024 9:59 AM
Cannabix Technologies to Deliver Innovative Breath Logix Alcohol Screening Device to Texas, USA • BLOZF • Jul 29, 2024 9:07 AM
BNCM AND DELEX UNVEIL POST-MERGER MANAGEMENT PLANS • BNCM • Jul 29, 2024 9:00 AM
Glidelogic Corp. Announces Revolutionary AI-Generated Content Copyright Protection Solution • GDLG • Jul 26, 2024 12:30 PM